Recent NKTR News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:02:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 08:11:19 PM
- Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 • PR Newswire (US) • 06/12/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:42 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/06/2024 04:15:16 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/05/2024 09:30:37 PM
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 10:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/28/2024 08:51:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:14:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:13:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:12:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:25:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:22:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:14:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:20:50 PM
- Nektar Therapeutics Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:15:00 PM
- Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets • PR Newswire (US) • 05/02/2024 10:00:00 PM
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference • PR Newswire (US) • 03/22/2024 06:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:11:03 PM
- Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata • PR Newswire (US) • 03/05/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:20:46 PM
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results • PR Newswire (US) • 03/04/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:40:59 PM
- Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX • PR Newswire (US) • 03/04/2024 01:30:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM